Is This Number The Biggest Risk To Intuitive Surgical Stock?

For questions about this article or underlying research, email help@trefis.com.

For holders of Intuitive Surgical (ISRG), the number to worry about is what the company earns on instruments and accessories each time a surgeon operates with a da Vinci system. Total instrument and accessory sales generated $1.8 billion of the company’s $3.05 billion in fiscal Q3 2026 revenue. On its October 20 call, management said it will charge less for da Vinci instruments. How big is that cut, and why is Intuitive making it?

How Deep Is Intuitive Surgical’s Instrument Price Cut?

Management expects its pricing changes and a price cut in China to lower da Vinci instrument revenue per procedure by about 3% to 5% once fully in place. That estimate holds the mix of procedures, products and countries steady, so it measures price alone.

Starting in November, a change in billing-code policy will bring a big reduction in Intuitive’s instrument prices in China. Elsewhere, management is aiming its pricing at high-volume operations such as hernia repair, where it said customers value reliability, efficiency and economics. These changes, which include longer-life instruments, roll out country by country from the first half of 2027.

Da Vinci instrument revenue per procedure rose to about $1,860 in fiscal Q3 2026 from $1,800 a year earlier, mainly because of more SP procedures and instruments made for da Vinci 5. That is a rise of about 3.3%, so the planned cut could take back a full year of gains, or more. Management said the shift toward da Vinci 5 and SP is left out of the 3% to 5% estimate and will add to revenue per procedure. Instrument and accessory sales grew 18% in the quarter, climbing faster than the 15% growth in total procedures, and a lower price per procedure would narrow that difference.

Can More Procedures Offset Intuitive Surgical’s Price Cut?

Based on management’s own forecast, procedure growth is far larger than the cut. The company narrowed its 2026 forecast for da Vinci procedure growth to 14% to 15%, from the 13.5% to 15.5% range it gave in July. That guidance covers 2026, while the broader pricing changes only begin in 2027. SP procedures grew 55% in fiscal Q3 2026, and management said revenue growth benefits as da Vinci 5, SP and Ion become a larger share of the business.

Management also raised its 2026 forecast for adjusted gross margin to 68.7% to 69.3%, up from 68% to 69%, adding that lower product costs lifted the margin in fiscal Q3 2026.

U.S. demand is the open question. U.S. da Vinci procedures grew 10% in fiscal Q3 2026, half the 20% growth seen outside the U.S. Management said it is watching lower ACA enrollment and changes to Medicaid eligibility, while calling the operating environment in China challenging.

Intuitive Surgical Stock Usually Falls Harder In Sell-Offs

Intuitive Surgical stock fell further than the S&P 500 in four of the five most recent market shocks. The deepest was the 2022 inflation shock, when it fell 49%, against 24% for the S&P 500. During the 2025 tariff shock, the stock fell 26%, against 19%.

The shares are also down 19.6% over the year to October 30, 2026, while the S&P 500 returned 11.3%. Even so, the stock trades at 51.0 times earnings, against 22.6 for the S&P 500, so the price likely assumes Intuitive keeps growing much faster than the market. Against its own past, the P/E is low. At the end of September, only 7 of the 40 quarter ends since the end of 2016 had a lower P/E. That ranking uses the end-of-September P/E of 48.0, not the current 51.0.

For a holder, the price cut is a real worry but a measured one. Management expects procedures to grow far faster than the cut this year, but it has not yet given a procedure forecast for 2027, when most of the cut lands. For the risk to be worth taking, Intuitive needs procedures in the U.S., as well as abroad, to keep growing well ahead of the drop in price. Intuitive is expected to report in January 2027, when management also plans to give its operating expense guidance and update its estimate of the long-term opportunity in soft tissue surgery. Da Vinci instrument revenue per procedure is the number to watch in that report.

What Would Another Fall In Intuitive Surgical Do To Your Plan?

A fall hurts most when one stock is a large part of what you own, and selling it to spread the risk can bring a large tax bill. Our partner advisory firm offers a free strategy review of ways to put a floor under a large position and unwind it with less tax.

Request A Free Strategy Review

Spot an error or want more like this? Tell us in 10 seconds.